Ajanta Pharma Share Price Falls 2.17% After Q1 Results

August 3, 2026
Posted by: Kunal Singla
Category: News

Ajanta Pharma falls 2.17% to Rs 3,362.00. Q1 FY27 PAT Rs 334 crore vs Rs 255 crore (+31% YoY). Revenue Rs 1,626 crore vs Rs 1,303 crore (+25% YoY).

The Ajanta Pharma share price fall after Q1 results theme was in focus on Friday, with Ajanta Pharma shares moving 2.17% to Rs 3,362.00, from a previous close of Rs 3,436.40, after the company reported its results for the quarter ended June 2026.

Ajanta Pharma reported a profit after tax of Rs 334 crore for Q1 FY27, against Rs 255 crore in the year-ago quarter, a change of +31%. Revenue for the quarter stood at Rs 1,626 crore, compared with Rs 1,303 crore a year earlier, a change of +25%.

Click Here – Get Free Investment Predictions

Table of Contents

Ajanta Pharma Q1 FY27 Results: Key Numbers

Metric	Q1 FY27	Q1 FY26	YoY Change
Profit After Tax	Rs 334 crore	Rs 255 crore	+31%
Revenue	Rs 1,626 crore	Rs 1,303 crore	+25%

Why Ajanta Pharma Shares Moved 2.17% Today

Check the Univest Screener for sector-linked stocks

Strong India branded generics and US sales drove the earnings beat, even as shares slipped on broader profit booking.

About Ajanta Pharma

Speciality pharmaceutical formulation company with branded generics in India, emerging markets and the US.

Download the Univest iOS App or Univest Android App to track Ajanta Pharma’s stock price and quarterly results.

What to Watch Going Forward

Investors tracking Ajanta Pharma should watch management commentary on demand trends, cost pressures and full-year guidance in the coming quarters, since forward-looking statements often matter as much as the headline quarterly numbers for how the stock trades over the following weeks.

Conclusion

The Ajanta Pharma share price fall after Q1 results move reflects the market’s reaction to the company’s latest quarterly performance. Investors should evaluate the stock against its own growth trajectory and valuation, and consult a SEBI-registered financial advisor before making any investment decision.

Investors continuing to track the Ajanta Pharma share price fall after Q1 results story should watch how the stock trades in the sessions ahead.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Ajanta pharma share price fall after q1 results

Why did Ajanta Pharma share price fall after Q1 results?

Ans. Ajanta Pharma shares moved 2.17% after the company reported Q1 FY27 profit after tax of Rs 334 crore, a change of +31% from Rs 255 crore a year earlier, on revenue of Rs 1,626 crore.

What was Ajanta Pharma’s profit in Q1 FY27?

Ans. Ajanta Pharma reported a profit after tax of Rs 334 crore for the quarter ended June 2026, compared with Rs 255 crore in the same quarter a year earlier.

What was Ajanta Pharma’s revenue in Q1 FY27?

Ans. Ajanta Pharma’s revenue for Q1 FY27 stood at Rs 1,626 crore, compared with Rs 1,303 crore a year earlier, a change of +25%.

What is Ajanta Pharma’s current share price?

Ans. Ajanta Pharma shares were trading at Rs 3,362.00 today, falling 2.17% from the previous close of Rs 3,436.40.

Should I buy Ajanta Pharma shares after the Q1 results move?

Ans. Investment decisions should be based on individual research and risk appetite; consult a SEBI-registered financial advisor before buying or selling shares after any results-driven move.

Where can I track Ajanta Pharma’s live share price?

Ans. Ajanta Pharma’s live share price and quarterly result updates can be tracked on the Univest platform alongside SEBI-registered research.

News

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.